Overview

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
0
Participant gender:
Male
Summary
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy male subjects following single or multiple ascending doses.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Suven Life Sciences Limited
Criteria
Inclusion Criteria:

• Healthy male aged 18 to 45 years with a BMI between 18 and 30 kg/m2, (inclusive).

Exclusion Criteria:

- Standard exclusion criterion for Phase 1 clinical trial in healthy subjects.

- History of any clinically significant disease or disorder which, in the opinion of the
Investigator, may either put the volunteer at risk because of participation in the
study, or influence the results or the volunteer's ability to participate

- History or presence of GI, hepatic, or renal disease or any other condition known to
interfere with absorption, distribution, metabolism, or excretion of drugs as judged
by Investigator.